Related Experiment Videos
Evaluation of human serum based tumor marker control.
The Journal of Nuclear Medicine and Allied Sciences
|July 1, 1989
Summary
A new bilevel human serum control for 13 cancer-associated antigens has been developed. This quality control product enhances the accuracy and precision of cancer diagnostic immunoassays.
Area of Science:
- Clinical Chemistry
- Immunodiagnostics
- Oncology
Background:
- Accurate cancer diagnostic testing relies on robust quality control measures.
- Existing controls may not cover a comprehensive panel of tumor markers.
- Ensuring the reliability of immunoassay results is critical for patient management.
Purpose of the Study:
- To develop and validate a comprehensive, bilevel human serum-based control for multiple tumor markers.
- To assess the stability and suitability of the control for routine quality assurance in cancer diagnostics.
Main Methods:
- Development of a human serum-based control containing 13 tumor-associated antigens.
- Bilevel design (Level I low, Level II elevated) to cover assay linear ranges.
- Stability testing of reconstituted and lyophilized material under various storage conditions.
- Validation using commercially available Radioimmunoassay (RIA) and Immunoradiometric Assay (IRMA) kits.
Main Results:
- The control includes a broad menu of traditional and novel cancer antigens (e.g., CA 125, CA 19-9, TPA, Beta-2-microglobulin, CEA, AFP, PAP).
- Reconstituted control shows stability for 14 days at 2-8°C and 30 days at -20°C.
- Lyophilized control demonstrates 3-year stability at 2-8°C.
- The control is azide-free, preventing immunoassay interference.
Conclusions:
- The developed tumor marker control provides a reliable tool for quality assurance in cancer antigen testing.
- It effectively aids in evaluating the accuracy and precision of various immunoassay methods.
- This product supports consistent and dependable cancer diagnostic testing.